Article
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
PloS one - 1 Jan 2012
Hofmann Irmgard, Weiss Andreas, Elain Gaelle, Schwaederle Maria, Sterker Dario, Romanet Vincent, Schmelzle Tobias, Lai Albert, Brachmann Saskia M, Bentires-Alj Mohamed, Roberts Thomas M, Sellers William R, Hofmann Francesco, Maira Sauveur-Michel
Abstract excerpt
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting components of these pathways. To better understand the requirements for K-RAS and its downstream signaling pathways MAPK...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.